Bipolar I disorder

Bipolar I is the high-stakes leaf of the bipolar spectrum: examiners test mania criteria, polarity-safe acute algorithms, lithium levels and anti-suicide evidence, maintenance after a first mania, and the absolute caution on valproate in pregnancy potential. A FRANZCP MEQ demands risk, legal status, named doses and monitoring; an MRCPsych CASC tests lithium explanation to a family; an ABPN item punishes antidepressant monotherapy and mis-timed troughs.[10][11][12]

Overview and definition

Bipolar I disorder is a chronic, recurrent mood disorder diagnosed when the patient has met criteria for at least one manic episode in their lifetime. A major depressive episode is not required for the diagnosis, though most patients develop depression. Substance and medical causes of mania must be reasonably excluded or distinguished as substance/medication-induced or secondary mania.[17]

Manic episode criteria (DSM-5-TR framing you must reproduce)

A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally increased activity or energy, lasting at least 7 consecutive days (or any duration if hospitalisation is required), present most of the day nearly every day, with marked impairment, need for hospitalisation, or psychotic features. At least three Criterion B symptoms (four if mood is only irritable) from: inflated self-esteem/grandiosity; decreased need for sleep; more talkative/pressured speech; flight of ideas or racing thoughts; distractibility; increase in goal-directed activity or psychomotor agitation; excessive involvement in risky activities. Symptoms are not better explained by substance/medical condition for primary bipolar I labelling.[17]

Critical discriminators. Psychosis during an elevated pole means mania, not hypomania — hypomania excludes psychotic features by definition. Hypomania lasts at least 4 consecutive days, is observable by others, and does not cause marked impairment or hospitalisation — a history of only hypomania plus depression is bipolar II, not bipolar I. ICD-11 uses manic episode and bipolar type I constructs with the same polarity logic; state thresholds with the manual you are citing in the exam room.[17]

Classification

Mixed features. During mania, co-occurring depressive symptoms (dysphoria, guilt, suicidal ideation) define a high-risk phenotype; during bipolar depression, manic symptoms (racing thoughts, decreased sleep need, pressure) likewise raise suicide and switch concern. Do not treat mixed bipolar I states as “agitated unipolar depression” with antidepressant alone.[10][11]

Rapid cycling. At least four full-criteria mood episodes in 12 months, demarcated by remission or polarity switch. Address antidepressants, substances, and thyroid disease as drivers, not only the label.[10][17]

Epidemiology and risk factors

World Mental Health Survey work shows bipolar spectrum conditions are more prevalent than older clinic estimates when bipolar II and subthreshold phenotypes are counted carefully; classical bipolar I remains less common than the broader spectrum but carries high hospitalisation and mortality burden.[15][17]

Precipitants and mortality. Sleep deprivation, stimulants, high-THC cannabis, antidepressants without mood-stabiliser cover, corticosteroids, postpartum upheaval, and severe stress are common proximal triggers — none is necessary or sufficient.[17][11] Excess mortality relates to suicide, accidents, and cardiometabolic disease. Lithium’s association with reduced suicidal behaviour is a core evidence talking point that coexists with mandatory renal/thyroid monitoring.[3][14]

Pathophysiology

Monoaminergic maps remain practical (dopamine and noradrenaline tone in mania; broader network failure in depression). Circadian and social-rhythm instability is both mechanism and treatment target: reduced sleep need with rising energy is the classic early warning of manic relapse. Kindling language (earlier episodes more triggered, later more autonomous) is useful if you avoid overclaiming universality. Lithium’s multi-target pharmacology (second messengers, GSK-3β pathway, neurotrophic effects) is explanatory, not a diagnostic test. Genetics are polygenic at group level; imaging does not diagnose the individual patient.[17][14]

Clinical presentation

Manic MSE — viva language. Mood elevated, expansive, or irritable. Speech pressured, difficult to interrupt. Thought form accelerated with flight of ideas or clang associations. Content grandiose (“I will restructure the hospital tonight”) or paranoid. Perception may include mood-congruent voices. Cognition: distractible, impaired judgement. Insight often lost. Sleep: decreased need with preserved or increased energy — highest-yield prodrome.[17]

Bipolar I depression. Cross-sectionally may mimic unipolar MDD. Longitudinal clues: early onset, highly recurrent course, postpartum episodes, family bipolar history, antidepressant-induced activation/switch, atypical features (hypersomnia, leaden paralysis), and buried high-energy intervals on collateral.[11][17]

Mixed and psychotic poles. Racing thoughts with tearfulness, agitation with guilt, decreased sleep with suicidal intent — lower admission threshold. Psychotic mania still follows mood chronology more often than primary schizophrenia, but always document the time course carefully for the schizoaffective differential.[10][17]

Differential diagnosis

[17] [11]

Organic differentials for first or atypical mania include hyperthyroidism, Cushing syndrome, MS, frontal lesions, HIV, neurosyphilis, autoimmune encephalitis, epilepsy, and delirium. Fluctuating attention means delirium until proven otherwise.[17][11]

Clinical and bedside assessment

Structure as polarity history + risk + capacity + collateral + medical exclusion.[11][12]

1. Lifetime chart: first pole and age; number of manias/depressions; psychosis; hospitalisations; postpartum; seasonality; antidepressant responses/switches; suicide attempts.
2. Current episode: duration, sleep hours, spending, sexual risk, aggression, driving, childcare, online behaviour.
3. MSE with quoted examples.
4. Risk: suicide (intent, plan, means, mixed features, alcohol), violence, sexual disinhibition, financial/forensic harm, vulnerability, absconding, child protection interface.
5. Capacity and legal status: understand, retain, weigh, communicate; least-restrictive care under local statute (do not invent foreign section numbers).
6. Collateral often confirms mania when the patient minimises risk.
7. Scales conceptually: YMRS (mania), MADRS/HAM-D (depression), CGI; mood charting and sleep diaries beat retrospective guesswork.[11][12]

Investigations

Before lithium, valproate, or an SGA, complete a safety baseline.[11][14]

• Bloods: FBC, U&E/eGFR, calcium, TFT, LFT, fasting glucose or HbA1c, lipids.
• ECG if cardiac risk, older age, or QT-prolonging agents planned.
• Weight/BMI, BP, waist; pregnancy test when relevant.
• Urine drug screen supports, does not exclude, primary bipolar I.
• CT/MRI, EEG, autoimmune panel when first/atypical mania, focal signs, seizure, or encephalitis features.[11][14]

Lithium levels are 12-hour troughs. Acute mania targets are often in the 0.8–1.2 mmol/L region; maintenance commonly 0.6–0.8 mmol/L, individualised. Toxicity risk rises substantially as levels climb above about 1.5 mmol/L; severe toxicity may present above 2.0 mmol/L. Check level about 5–7 days after initiation or dose change, when stable periodically, and after interacting drugs, dehydration, or renal change.[14][12]

Management — acute / emergency

Agitation ladder. De-escalate first. Offer oral medication before IM when safe. Short-term benzodiazepines (for example lorazepam oral/IM per protocol) for arousal and sleep. Antipsychotic IM options per local protocol; avoid hazardous combinations (notably parenteral olanzapine with parenteral benzodiazepines in many safety frameworks). Document capacity and least-restrictive legal pathway.[11]

Lithium toxicity emergency. Stop lithium, urgent level and renal function, IV fluids as indicated, cardiac monitoring, higher-level care for severe neurotoxicity — dialysis pathway for life-threatening toxicity per medical toxicology. Precipitants: NSAIDs, ACE inhibitors/ARBs, thiazides, dehydration, intercurrent illness.[14]

Management — definitive and stepwise

Acute mania algorithm

Network meta-analysis supports multiple antimanic agents; ranking varies by efficacy and acceptability, with several SGAs, lithium, and valproate in the effective set.[4] Landmark divalproex versus lithium versus placebo mania data established anticonvulsant antimanic efficacy alongside lithium.[16]

Practical first-line options (adult illustrative frameworks — localise to product information and comorbidity). Guideline hierarchies and trial practice support lithium, valproate and several SGAs for acute mania.[4][10][16]

Severe mania frequently needs combination mood stabiliser plus SGA. ECT remains highly effective for refractory, exhausted, catatonic, or life-threatening mania.[10][11][4]

Bipolar I depression algorithm

Evidence-backed polarity-safe options include the following pathways.[10][11]

• Quetiapine monotherapy: BOLDER programme supports efficacy in bipolar depression; common effective range 300–600 mg oral at night (titrate; metabolic burden).[6][18]
• Lurasidone monotherapy: 20–120 mg oral daily with food in bipolar I depression trials.[8]
• Olanzapine–fluoxetine combination (OFC): positive bipolar I depression data versus placebo; metabolic cost of olanzapine requires active monitoring.[7]
• Lamotrigine: stronger for maintenance depression prevention than as a fast acute antidepressant. Titrate carefully (classic adult schedule often 25 mg daily oral for 2 weeks, 50 mg for 2 weeks, then upward toward 200 mg/day as tolerated; slower with valproate). Stop and urgent review for concerning rash (SJS/TEN risk).[9]
• Lithium: antisuicide and maintenance value; modest acute antidepressant effect in some comparative data.[3][9]

Antidepressants — STEP-BD lesson. Adjunctive paroxetine or bupropion added to a mood stabiliser did not outperform mood stabiliser plus placebo for durable recovery — a foundational challenge to casual antidepressant use.[2] If an antidepressant is used in bipolar I, cover with a mood stabiliser, never use monotherapy, keep duration short, and monitor sleep/activation closely.[2][10]

Maintenance and relapse prevention

BALANCE (bipolar I relapse prevention) showed lithium monotherapy superior to valproate monotherapy, with combination lithium–valproate also effective; lithium remains the maintenance cornerstone when tolerated.[1] Network meta-analysis of maintenance treatments supports lithium among the most robust long-term options, with several SGAs and anticonvulsants in the comparative set depending on index pole and tolerability.[5] Lamotrigine’s maintenance signal is relatively stronger for delaying depressive recurrence; lithium covers both poles more evenly in classic pooled data.[9]

Lithium practicalities. Educate on hydration, sodium balance, and interacting drugs. McKnight’s systematic review quantifies long-term renal, thyroid, and parathyroid risks — monitor rather than mythologise.[14] Cipriani meta-analysis supports lithium for suicide prevention in mood disorders — one of the few pharmacotherapies with this signal.[3]

Psychological and social care. Psychoeducation, interpersonal and social rhythm therapy (IPSRT), CBT adapted for bipolar disorder, and family-focused approaches reduce relapse risk as adjuncts to medication. Sleep regularity is a treatment. Address alcohol and stimulants aggressively.[10][11][12]

After a first manic episode, many frameworks plan at least 6–12 months of maintenance, longer if high risk, residual symptoms, or strong family pattern — individualise with shared decision-making.[11][10]

Specific subtypes and scenarios

First manic episode. Medical exclusion, risk, start antimanic therapy, decide legal status, begin psychoeducation, establish monitoring logistics, and plan maintenance before discharge.[11][10]

Psychotic mania. Mood stabiliser ± SGA combination is common; ECT if exhausted, catatonic, or refractory. Document psychosis chronology for the schizoaffective interface.[10][4]

Mixed features and rapid cycling. Treat mixed as high-risk bipolar I: SGA ± lithium/valproate, restore sleep, hold antidepressants. For rapid cycling: remove cycle accelerators, correct thyroid disease, optimise lithium/valproate/SGA, consider lamotrigine for depression burden, use mood charting — single-agent “rapid-cycling drug” evidence is weaker than classic bipolar I maintenance.[10][17]

Forensic and risk interfaces. Financial ruin, sexual disinhibition, driving, and child protection may all require multi-agency action while treating the pole — document capacity and risk explicitly.[11]

Complications and pitfalls

• Antidepressant monotherapy and unrecognised switch in bipolar I.[2]
• Lithium prescribed without interaction counselling (NSAIDs, ACEI/ARB, thiazides) or trough timing education.[14]
• Valproate exposure in pregnancy-capable patients without prevention programme.[11][12]
• Metabolic syndrome from olanzapine/quetiapine ignored; akathisia mislabelled as worsening mania.[10]
• Secondary mania missed in older adults; residual elevated mood mistaken for “recovered and happy.”[17][11]

Prognosis and disposition

Most people with bipolar I have recurrent episodes; inter-episode recovery is possible but residual depressive symptoms and functional gaps are common. Better prognosis associates with adherence, absence of substance use, good premorbid function, and fewer mixed/rapid-cycling features. Admit for dangerous mania/mixed states, severe suicidality, psychosis with impaired judgement, or failed community containment. Step down with early-warning-sign plans, sleep targets, lithium/level logistics, and rapid re-access pathways.[17][5][3]

Special populations

Youth. Diagnostic caution for non-episodic chronic irritability (not automatically bipolar I). Specialist oversight for lithium and family work.[17]

Older adults. Higher rates of secondary mania; reduce lithium dose for renal clearance; watch delirium, falls, and polypharmacy interactions.[14]

Pregnancy and postpartum. Preconception counselling is mandatory. Valproate sits at the top of the teratogenicity concern hierarchy (neural tube defects, neurodevelopmental harm) and is generally avoided in people who can become pregnant unless exceptional circumstances and formal prevention programmes apply.[11][12] Lithium has a measurable increase in cardiac malformation risk in large observational data, but absolute risks are lower than older dogma implied — Patorno et al. inform nuanced shared decision rather than automatic cessation in every stable patient.[13] Lamotrigine and selected SGAs are often considered. Postpartum is a peak relapse window: protect sleep, plan prophylaxis restart, coordinate maternity–psychiatry care.[13][11][10]

Lactation. Lithium often avoided or used only with intensive infant monitoring in specialist settings; many prefer alternatives. Individualise with paediatric liaison.[11]

Evidence, guidelines and regional differences

Landmark trials to name. BALANCE (Li vs VPA vs combination in bipolar I); STEP-BD adjunctive antidepressants; BOLDER quetiapine; OFC; lamotrigine maintenance pooled analyses; Cipriani antimanic NMA; Miura maintenance NMA; Cipriani lithium–suicide meta-analysis; Patorno lithium–pregnancy cardiac malformations; Bowden divalproex mania.[1][2][4][5][6][7][9][3][13][16]

Exam pearls

[11] [10]

References

1. [1]BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
2. [2]Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression N Engl J Med, 2007.PMID 17392295
3. [3]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
4. [4]Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis Lancet, 2011.PMID 21851976
5. [5]Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis Lancet Psychiatry, 2014.PMID 26360999
6. [6]Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am J Psychiatry, 2005.PMID 15994719
7. [7]Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression Arch Gen Psychiatry, 2003.PMID 14609883
8. [8]Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am J Psychiatry, 2014.PMID 24170180
9. [9]Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder J Clin Psychiatry, 2004.PMID 15096085
10. [10]Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder Bipolar Disord, 2018.PMID 29536616
11. [11]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
12. [12]Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology J Psychopharmacol, 2016.PMID 26979387
13. [13]Patorno E, Huybrechts KF, Hernandez-Diaz S Lithium Use in Pregnancy and the Risk of Cardiac Malformations N Engl J Med, 2017.PMID 28854098
14. [14]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
15. [15]Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative Arch Gen Psychiatry, 2011.PMID 21383262
16. [16]Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group JAMA, 1994.PMID 8120960
17. [17]Grande I, Berk M, Birmaher B, et al. Bipolar disorder Lancet, 2016.PMID 26388529
18. [18]Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J Clin Psychopharmacol, 2006.PMID 17110817